Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gross Profit (2023 - 2025)

Mirum Pharmaceuticals has reported Gross Profit over the past 3 years, most recently at $120.7 million for Q4 2025.

  • Quarterly results put Gross Profit at $120.7 million for Q4 2025, up 57.46% from a year ago — trailing twelve months through Dec 2025 was $421.1 million (up 64.97% YoY), and the annual figure for FY2025 was $421.1 million, up 64.97%.
  • Gross Profit for Q4 2025 was $120.7 million at Mirum Pharmaceuticals, up from $107.5 million in the prior quarter.
  • Over the last five years, Gross Profit for MIRM hit a ceiling of $120.7 million in Q4 2025 and a floor of $26.6 million in Q1 2023.
  • Median Gross Profit over the past 3 years was $63.6 million (2024), compared with a mean of $68.0 million.
  • Biggest five-year swings in Gross Profit: soared 93.07% in 2024 and later soared 54.48% in 2025.
  • Mirum Pharmaceuticals' Gross Profit stood at $44.5 million in 2023, then surged by 72.08% to $76.6 million in 2024, then soared by 57.46% to $120.7 million in 2025.
  • The last three reported values for Gross Profit were $120.7 million (Q4 2025), $107.5 million (Q3 2025), and $104.4 million (Q2 2025) per Business Quant data.